Microcap Ledger Senti Biosciences Holdings, Inc. $SNTI
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- South San Francisco, CA
- Fiscal year end
- December 31
- Shares outstanding
- 31,144,754 [10-Q 2026-08-14]
What the company doesAI summary of filing
Senti Biosciences is a clinical-stage biotechnology company developing cell and gene therapies using its proprietary gene circuit platform technologies. The company's lead product candidate, SENTI-202, is an off-the-shelf CAR-NK cell therapy currently in a Phase 1 clinical trial for relapsed/refractory acute myeloid leukemia and other hematologic malignancies; initial data from 20 patients showed a 50% overall response rate and a favorable safety profile. The company also has preclinical programs in solid tumor cell therapy and a partnership with BlueRock Therapeutics for regenerative medicine applications. Senti is pre-revenue and generates income through research collaborations and licensing agreements, including arrangements with the National Cancer Institute for FLT3 and CD33 technology, and a former collaboration with Spark Therapeutics. [10-K 2026-03-27]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $33.0K | −$16.97M | −$21.73M | $6.46M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | $22.0K | −$61.44M | −$43.44M | $16.42M | [10-K 2026-03-27] |
| FY ended Dec 2024 | $0.00 | −$52.79M | −$41.40M | $48.28M | [10-K 2025-03-20] |
- Quarterly cash burn
- −$10.87M
- Cash runway Estimate
- ~1.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-03-18 | 26,004,366 | [10-K 2025-03-20] |
| 2025-04-30 | 26,081,139 | [10-Q 2025-05-06] |
| 2025-07-31 | 26,160,206 | [10-Q 2025-08-07] |
| 2025-10-31 | 26,290,838 | [10-Q 2025-11-13] |
| 2026-03-19 | 31,144,497 | [10-K 2026-03-27] |
| 2026-04-22 | 31,144,754 | [10-K/A 2026-04-29] |
| 2026-04-30 | 31,144,754 | [10-Q 2026-05-14] |
| 2026-07-31 | 31,144,754 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2026-06-18; declared effective 2026-09-24 [S-3 2026-06-18]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-09-02. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-09-02 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-09-02] |
| 2024-10-25 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-10-25] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-03-09 | Rajangam Kanya | other | 10,757 | — | [4 2026-03-11] |
| 2026-03-09 | Lu Timothy K | other | 80,666 | — | [4 2026-03-11] |
| 2026-02-02 | Rajangam Kanya | other | 1,384 | — | [4 2026-02-03] |
| 2026-02-02 | Lu Timothy K | other | 4,191 | — | [4 2026-02-03] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-24 | 424B3 | Prospectus or prospectus supplement |
| 2026-09-24 | 8-K | Director or officer change |
| 2026-09-22 | S-3/A | Registration statement |
| 2026-09-11 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-09-10 | S-3/A | Registration statement |
| 2026-09-04 | 8-K | Material agreement entered; New financial obligation |
| 2026-09-02 | 8-K | Material agreement entered; Listing notice or transfer |
| 2026-08-20 | 8-K | Material agreement entered; New financial obligation |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-07-16 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-07-16 | S-3/A | Registration statement |
| 2026-07-15 | 8-K | Material agreement entered; Results of operations; Change in control |
Alerts for $SNTI
Email me when Senti Biosciences Holdings, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.